The Claim
Once-weekly insulin icodec improves treatment compliance in diabetic patients undergoing anal fistula surgery compared to daily insulin regimens, enabling more stable perioperative glycemic control.
What the research says
Roughly balanced
Support and challenge are close. The picture may shift as more studies come in.
These are independent scores, not a percentage. Higher-grade studies count more, so a single strong opposing study can outweigh several weaker ones.
Diabetic patients undergoing anal fistula surgery who receive once-weekly insulin icodec have better adherence to their insulin regimen and more stable blood sugar levels during surgery compared to those receiving daily insulin.
See the scientific wording
Once-weekly insulin icodec improves treatment compliance in diabetic patients undergoing anal fistula surgery compared to daily insulin regimens, enabling more stable perioperative glycemic control.
Giving insulin once a week keeps blood sugar levels steady, which stops the body from making too many harmful sugars that cause swelling, weaken the immune system, and block oxygen from reaching the wound. This lets the body heal the surgery site faster and fight off infections better.
What the research says
1 studyThe study says that using a once-a-week insulin shot helps diabetic patients stick to their treatment better than daily shots when they’re recovering from anal fistula surgery, which helps keep their blood sugar more stable.
Score breakdown, mechanism chain, raw evidence, ideal studies needed & 1 supporting studies
Not medical advice. For informational purposes only. Always consult a qualified healthcare professional before making health decisions.